References
1 David L S, Frederick W, Tom WJH. Rheumatoid arthritis. Lancet2010; 376 : 1094-108.
2 Miguel AG, Carlos G, Javier M, J. Rheumatoid arthritis: a disease
associated with accelerated atherogenesis. Semin Arthritis Rheum2005; 35 : 8-17.
3 Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et
al. Lipids, myocardial infarction and ischaemic stroke in patients with
rheumatoid arthritis in the Apolipoprotein-related Mortality RISk
(AMORIS) Study. Ann Rheum Dis 2010; 69 : 1996-2001.
4 Nicola JG, Nicola JW, Mark L, Elizabeth MB, Alan JS, Deboran PMS.
Mortality in early inflammatory polyarthritis: cardiovascular mortality
is increased in seropositive patients. Arthritis Rheum 2002;46 : 2010-19.
5 Paulo JN, Hilal M, Veronique LR, Steven JJ, Cynthia SC, Karla VB, et
al. The risk of congestive heart failure in rheumatoid arthritis: a
population-based study over 46 years. Arthritis Rheum 2005;52 : 412-20.
6 Maarten B, Ben D, Sherine G, Hilal MK, James O, Theodore P. Making an
impact on mortality in rheumatoid arthritis: targeting cardiovascular
comorbidity. Arthritis Rheum 2004; 50 : 1734-39.
7 Raquel CLRE. Does TNF-alpha blockade play any role in cardiovascular
risk among rheumatoid arthritis (RA) patients? Clin Rheumatol2009; 28 : 1217-20.
8 Ljung L, Olsson T, Engstrand S, Wållberg- Jonsson S, Söderberg S,
Rantapää-Dahlqvist. Interleukin-1 receptor antagonist is associated with
both lipid metabolism and inflammation in rheumatoid arthritis.Clin Exp Rheumatol 2007; 25 : 617-20.
9 Misato H, Hiroto Y, Nobuo K, Miho S, Masahiko M. Overproduced
interleukin 6 decreases blood lipid levels via upregulation of
very-low-density lipoprotein receptor. Ann Rheum Dis 2010;69 : 741-6.
10 Firestein GS. Evolving concepts of rheumatoid arthritis. Nat .
2003 ;423 : 356-61.
11 Ernest HSC, Gabriel SP. Cytokine pathways and joint inflammation in
rheumatoid arthritis. N Engl J Med 2001; 344 : 907-16.
12 Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents
and dietary intervention on insulin resistance and dyslipidemia in
inflammatory arthritis: a pilot study. Arthritis Res 2002;4 : R12.
13 Bloomgarden ZT. Insulin resistance, dyslipidemia, and cardiovascular
disease. Diabetes Care 2007; 30 : 2164-70.
14 Rader DJ. Effect of insulin resistance, dyslipidemia, and
intra-abdominal adiposity on the development of cardiovascular disease
and diabetes mellitus. Am J Med 2007; 120 ( Suppl 1):
S12-8.
15 Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it
all about inflammation? Nat Rev Rheumatol 2015; 11 :
390-400.
16 Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van
Riel PL, Barerra P. Influence of anti-tumour necrosis factor therapy on
cardiovascular risk factors in patients with active rheumatoid
arthritis. Ann Rheum Dis 2005; 64 : 303-5.
17 Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards
an atherogenic lipid profile in rheumatoid arthritis patients during
long-term infliximab therapy. Scand J Rheumatol 2006;35 : 107-11.
18 Marijn V, Michael TN, Gertjan W, Alexandre EV, Margret HMT, Rob J, et
al. Short term effects of infliximab on the lipid profile in patients
with rheumatoid arthritis. J Rheumatol 2005; 32 : 252-5.
19 Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of
repeated infliximab therapy on serum lipid profile in patients with
refractory rheumatoid arthritis. Clin Chim Acta 2006;365 : 143-8.
20 Dimitrios NK, Anastasios KM, Theodosios DF, Spyros V, Spyros NN,
Alexandros AD. Effects of infliximab treatment on lipoprotein profile in
patients with rheumatoid arthritis and ankylosing spondylitis. J
Rheumatol 2006; 33 : 921-3.
21 Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP.
Adalimumab: long-term safety in 23458 patients from global clinical
trials in rheumatoid arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s
disease. Ann Rheum Dis 2013; 72 : 517-24.
22 Dinglei S, Minning S, Bingjie G, Xiaoqin W, Dandan W,Xia L, et al.99Tc-methylene diphosphonate improves rheumatoid
arthritis disease activity by increasing the frequency of peripheral cd
T cells and CD4+CD25+Foxp3+Tregs. Int J Rheum Dis 2016;19 : 586-93.
23 Rong M, Jun L, Lingyun S, Zhuoli Z, Xiangyuan L, Cibo H, et al. A
randomized multicenter clinical trial of 99Tc-methylene diphosphonate in
treatment of rheumatoid arthritis. Int J Rheum Dis 2018;21 : 161-8.
24 Ying N, Jiaxin Z, Min F, Xinyu W, Xuewu Z. Effects of 99Tc -MDP on
tibial microarchitecture of glucocorticoid -induced osteoporotic rats
(in Chinese). J China-Japan Friendship Hospital 2011;25 : 216-9.
25 Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids
on radiological progression in rheumatoid arthritis. Cochrane
Database Syst Rev 2007: CD006356.
26 Davis JM, 3rd, Maradit KH, Crowson CS, Nicola PJ, Ballman KV,
Therneau TM, et al. Glucocorticoids and cardiovascular events in
rheumatoid arthritis: a population-based cohort study. Arthritis
Rheum 2007; 56 : 820-30.
27 Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO,
3rd, et al. 2010 Rheumatoid arthritis classification criteria: an
American College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis Rheum 2010; 62 :
2569-81.
28 Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone
acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and
certain other conditions. Arch Intern Med (Chic) 1950;85 : 545-666.
29 Hillier SG. Diamonds are forever: the cortisone legacy. J
Endocrinol 2007; 195 : 1-6.
30 Irshad M, Dubey R. Apolipoproteins and their role in different
clinical conditions: An overview. Indian J Biochem Biophys 2005;42 : 73-80.
31 Steven AG, Louis C, Xiao-Ping H. Identifying Adults at Increased Risk
of Coronary Disease. JAMA 1995; 274 : 801-6.
32 Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and Lipids in
Relation to Inflammation in Rheumatoid Arthritis. Clin Rheumatol2000; 19 : 324-5.
33 Salim Y, Steven H, Stephanie Ô, Tony D, Alvaro A, Fernando L, et al.
Effect of potentially modifiable risk factors associated with myocardial
infarction in 52 countries (the INTERHEART study): case-control study.Lancet 2004; 364 : 937-53.
34 Walldius G. The apoB/apoA-I Ratio is a Strong Predictor of
Cardiovascular Risk. In: Sasa F, Gerhard F, eds. Lipoproteins - Role in
Health and Diseases. Intechopen (www.intechopen.com) 2012: 95-148.
35 McQueen MJ, Steven H, Xingyu W, Stephanie O, Allan S, Jeffrey P,et
al. Lipids, lipoproteins, and apolipoproteins as risk markers of
myocardial infarction in 52 countries (the INTERHEART study): a
case-control study. Lancet 2008; 372 : 224-33.
36 John MD, 3rd, Hilal MK, Sherine EG. Use of low-dose glucocorticoids
and the risk of cardiovascular morbidity and mortality in rheumatoid
arthritis: what is the true direction of effect? J Rheumatol2005; 32 : 1856-62.
37 Ross IL, Marais AD. The influence of glucocorticoids on lipid and
lipoprotein metabolism and atherosclerosis. S Afr Med J 2014;104 : 671-4.
38 Peters MJL, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, et
al. Changes in lipid profile during infliximab and corticosteroid
treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66 : 958-61.
39 Garcia-Gomez C, Nolla JM, Valverde J, Narvaez J, Corbella E, Pinto X.
High HDL-cholesterol in women with rheumatoid arthritis on low-dose
glucocorticoid therapy. Eur J Clin Invest 2008; 38 :
686-92.
40 van der Goes MC, Jacobs JWG, Boers M, Andrews T, Blom-Bakkers MAM,
Buttgereit F, et al. Monitoring adverse events of low-dose
glucocorticoid therapy: EULAR recommendations for clinical trials and
daily practice. Ann Rheum Dis 2010; 69 : 1913-19.
41 Miller LW. Cardiovascular Toxicities of Immunosuppressive Agents.Am J Transplant 2002; 2 : 807-18.
42 Ettinger WH, Jr., Hazzard WR. Elevated apolipoprotein-B levels in
corticosteroid-treated patients with systemic lupus erythematosus.J Clin Endocrinol Metab 1988; 67 : 425-8.
43 Stern MP, Kolterman OG, Fries JF, McDevitt HO, Reaven GM.
Adrenocortical Steroid Treatment of Rheumatic Diseases. Arch
Intern Med 1973; 132 : 97-101.